Forum Agenda

July 23, 09:00-10:20

Panel Discussion: AI-Enabled Four-in-One Translational Platform

Stay tuned

Conference Time: July 23, 09:00-10:20

 

Planner
Danyi Wen: Founder, Chairman & Executive President, LIDE Biotech

 

09:00-10:00 Panel Discussion: AI-Enabled Four-in-One Translational Platform
Danyi Wen (Host): Founder, Chairman & Executive President, LIDE Biotech
Jin Li (subject to change): President, Shanghai GoBroad Cancer Hospital
Chen Zhao: Professor, Nanjing Medical University
Bin Xie: VP of Research, Executive Director of Immuno-oncology, LIDE Biotech
Jiaxin Liu: Managing Director, Bayes Data
Hefei Zhang: Early Development, Clinical Research Executive Director, MSD
Xueyuan Zhang: Clinical Division Clinical Pharmacology Center Deputy General Manager, CSPC Pharmaceutical Group
Bin Yang: Global Clinical Development SVP, Global Operation Head, HUTCHMED
Lily Zhang: Founder & CEO, TTM Capital

 

10:00-10:20 Break

July 24, 13:00–16:00

AI·Intelligent Transformation: From Data Foundation to Scenario Value

Stay tuned

Conference Time: July 24, 13:00–16:00

 

13:30-13:35 Opening Remarks
Ruirong Yang: Partner, Marathon Venture (Beijing)

 

13:35-13:50 AI-Driven Development of New Quality Productive Forces in Healthcare & Investment Frontiers
Yinan Tang: Managing Director, Marathon Venture

 

13:50-14:05 From Data Foundation to Decision Intelligence: How InsRx OS Is Driving Professional Health Insurance into the Era of Intelligent Operations
Qiao Gong: Senior Vice President & Chief Product Officer, MediTrust Health

 

14:05-14:20 AI Combined with Organoids: Transforming Preclinical New Drug Discovery
Liuqi Huang: Vice President, bioGenous Biotechnology

 

14:20-14:35 Exploring the Frontiers of the Healthcare World Model
Du Zhao: Co-founder & Chief Financial Officer, SenseTime

 

14:35-14:50 SurgSmart: Connecting Data with Scenarios to Deliver Clinical Value
Xin Wang: Co-Founder, WithAI Innovation

 

14:50-15:05 Construction & Clinical Application of AI-Enabled Cardiovascular Chronic Disease Management System
Chuan Liu: Chief Medical Officer, HeartMed

 

15:05-16:00 Panel Discussion: Why Is China the Next Frontier for Global Medical AI?
Ruirong Yang: Partner, Marathon Venture (Beijing)
Yinan Tang: Managing Director, Marathon Venture
Qiao Gong: Senior Vice President & Chief Product Officer, MediTrust Health
Liuqi Huang: Vice President, bioGenous Biotechnology
Du Zhao: Co-founder & Chief Financial Officer, SenseTime
Xin Wang: Co-Founder, WithAI Innovation
Chuan Liu: Chief Medical Officer, HeartMed

July 24,10:20-11:35

AI-Driven Innovation in Biopharma

Stay tuned

10:20-10:35 AI Drug Discovery Reaches the Result-Validation Stage: From Financing Rebound to BD Acceleration Amid Result Validation
Jacky Lu: Strategy & Business Development Director, DXY Insight Database

 

10:35-10:50 From AI Discovery to Clinical Approval: How CROs Bridge the Last Mile of Drug Development
Ying Liu: Vice President, Clinical Trial Operations, Yidu Tech

 

10:50-11:05 Globalization Through an AI-Native Lens
Jacky: Head of AI, IASO Biotechnologies

 

11:05-11:20 Clinical Data Management: Dual-Engine Application of OCR & AI Medical Monitoring for EDC
Haiying Lin: Deputy General Manager, Jiutai CRO

 

11:20-11:35 Safe Takeoff in the Era of Super Intelligent Agents: Compliance Governance and Trustworthy AI Framework for Innovative Drugs in China
Nanchi Zhang: Partner, Risk Management and Decision Innovation, EY Consulting

July 22,10:00-12:30

The Era of Superintelligent Agents for Chinese Innovative Drugs

Stay tuned

Meeting Planner
Yuguang Wang (Founder & CEO, Tushenzhihé)


10:00-10:05 Opening Address


10:05-10:25 Allosteric Modulation of STING: A Novel Strategyfor Autoimmune Diseases
Ao Zhang:Dean, School of Pharmacy, Shanghai Jiao Tong University; Founder, Nauture Biotech


10:25-10:45 Ecological Reconstruction, Intelligent Leap: The Innovative Narrative of Chinese Biopharmaceuticals
Xin Xie:Executive Director & Senior Vice President, Sino Biopharmaceutical Limited; Senior Vice President, CP Pharmaceutical Group


10:45-11:00 Break


11:00-11:20 Macromolecular Drug Discovery and Development in the Era of AI Agents
Weining Lin:Chief AI Scientist, Toursun Synbio


11:20-11:40 De Novo Design of Miniproteins and Antibodies via Generative AI
Vice President, Toursun Synbio

 

11:40-11:50签约仪式Signing Ceremony
11:40-11:50 Signing Ceremony

Xiaomeng Sun:General Manager, Shanghai Minhang Biomedical Industry Development Co., Ltd.

Xin Xie:Executive Director & Senior Vice President, Sino Biopharmaceutical Limited; Senior Vice President, CP Pharmaceutical Group

Yuguang Wang:Founder & CEO, Toursun Synbio


11:50-12:30 Roundtable: AI-Native Biologics R&D: How Can Scientific Superintelligence Break the Boundaries of Drug Discovery?
Bingshi Guo (Moderator):General Manager, Macromolecular Drug Division, JeYou Pharmaceutical Technology

Jingjun Qiu:Global Partner, Fosun Pharma

Nan Gao:COO, InnoCare Pharma

Dan Liu:Partner, Pivotal Bioventure Capital

Yan Zhang:Co-founder & Vice President, MegaRobo Technologies

Yuguang Wang:Founder & CEO, Toursun Synbio

July 23, 14:00–17:30

AI for Science Reshaping Innovative Drug R&D Session

Stay tuned

Meeting Planner
Weijie Sun:Founder & CEO, DP Technology

 

14:00-14:10   Opening speech


14:10-14:30   AI for Science Infrastructure Development
Weijie Sun:Founder & CEO, DP Technology


14:30-14:50   AI & Robotics Empower Drug Discovery: Road to Autonomous Scientific Research
Jian Ma:Co-Founder & CEO,Xtalpi


14:50-15:10   From Technological Breakthroughs to Clinical Validation: The Second Half of AI-Driven Drug Development
Feng Ren:Co-CEO & CSO,Insilico Medicine


15:10-15:30   A New Paradigm in Drug Discovery: The Closed-Loop Leap with World Models and AI Scientists
Jeff He:Co-Founder & CEO,TandemAI


15:30-15:50   Tea  Break


15:50-16:10   Applications of Artificial Intelligence in Peptide Drug Discovery
Frank Zhang:Co-Founder & CEO,Syneron Bio


16:10-16:30   AI-Driven New Drug R&D: The Intelligent Revolution in Drug Delivery
Chris Lai:Co-Founder, Chairman & CEO, METiS TechBio 


16:30-16:50   AI Scientists Empower the Discovery and Validation of Novel Original Targets
Shuangjia Zheng:Researcher, Lingang Laboratory; Associate Professor, Shanghai Jiao Tong University


16:50-17:30   Roundtable: The Ultimate Competitiveness of AI Drug R&D — Differentiated Innovation or Original Source Innovation?
Weijie Sun:Founder & CEO, DP Technology
Jian Ma:Co-Founder & CEO,Xtalpi
Feng Ren:Co-CEO & CSO, Insilico Medicine
Jeff He:Co-Founder & CEO,TandemAI
Frank Zhang:Co-Founder & CEO,Syneron Bio
Chris Lai:Co-Founder, Chairman & CEO, METiS TechBio 
Shuangjia Zheng:Researcher, Lingang Laboratory; Associate Professor, Shanghai Jiao Tong University

July 22,15:50-17:40

AI Reshaping the End-to-End Clinical R&D Session

Stay tuned

Meeting Planner & Moderator: Shanshan Zhao – CEO, Q2BI

 

15:50-15:55 Opening Address
Shanshan Zhao: CEO, Q2BI

 

15:55-16:10 Efficiency Leap in Clinical R&D: AI-Driven Next-Generation Growth Engine
Simon Lin: Vice President of Biometrics, Q2BI

 

16:10-16:25 Medical Research "Autopilot": AI Agents Accelerating Clinical Data Governance and Statistical Practice
Meishuo Ouyang: Vice President, XY Health

 

16:25-16:40 From General-Purpose to Vertical: How AI Agents Crack Real Pain Points in Clinical R&D
Weijie Deng: Senior Manager of Biometrics, Q2BI

 

16:40-16:55 Smart Money's Judgment: When Will the Clinical AI Sector Take Off?
Haiyong Mo: Executive Vice President, Guangdong China Science and Tech Innovation Venture Capital Management Co., Ltd.

 

16:55-17:40 Roundtable: Real-Time Clinical Trials — From FDA Vision to AI Implementation
Moderator:
Shanshan Zhao (CEO, Q2BI)
Panelists:
Yaning Wang (Founder & CEO, Ruiningkang Pharma; Former Director at FDA)
Yehua Zhu (Vice President of Clinical Development, Elpiscience)
Will Ma (Founder & CEO, HopeAI)
Jian Lun (CEO, XY Health)
Simon Lin (Vice President of Biometrics, Q2BI)